Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles

Lijuan Chong, Yao‐Wen Jiang, Dongxu Wang, Pengzhao Chang, Kai Xu, Jingjing LiJournal of Nanobiotechnology 2023 · DOI

This research paper, published in the Journal of Nanobiotechnology, describes the development of a "smart" biomimetic nanoparticle designed to reprogram the immune environment of a tumor. By disguising a drug-loaded core with a macrophage membrane and a targeting peptide, the researchers successfully converted pro-tumor macrophages into anti-tumor fighters while simultaneously enabling high-contrast MRI tracking of the tumor.

TL;DR

Researchers have developed a biomimetic nanoparticle (HMMDN-Met@PM) that targets "pro-tumor" M2 macrophages and "repolarizes" them into "anti-tumor" M1 macrophages using metformin. This "Trojan Horse" approach not only inhibits tumor growth by 84.7% in mouse models but also provides a responsive MRI contrast agent that activates specifically within the tumor microenvironment.

What Problem Does This Paper Address?

The tumor microenvironment (TME) is notoriously immunosuppressive. A major culprit is the Tumor-Associated Macrophage (TAM). TAMs generally exist in two states: M1-like (classically activated, anti-tumor) and M2-like (alternatively activated, pro-tumor). In most aggressive cancers, M2-like macrophages dominate, helping the tumor grow, evade the immune system, and metastasize.

While immunotherapy is a promising field, delivering drugs specifically to these M2 macrophages without systemic toxicity is difficult. Furthermore, clinicians need better ways to monitor whether an immunotherapy is actually working in real-time. This paper addresses the dual challenge of targeted macrophage repolarization and responsive diagnostic imaging.

Methods

The authors constructed a multi-layered nanoparticle called HMMDN-Met@PM:

  1. The Core: They synthesized hollow mesoporous manganese dioxide (HMMDN) nanoparticles. The hollow structure allows for high loading of Metformin (Met), a common diabetes drug recently discovered to have potent immune-modulating properties.
  2. The Disguise: To prevent the body’s immune system from clearing the particles (the "foreign body" response), they coated the core with a natural macrophage membrane (MM).
  3. The GPS: They modified the membrane surface with M2pep, a peptide that specifically binds to M2-like macrophages.
  4. The Trigger: The $MnO_2$ core is chemically responsive. In the acidic and glutathione (GSH)-rich environment of a tumor, the $MnO_2$ decomposes into $Mn^{2+}$ ions.

Datasets

As a laboratory study in nanotechnology and oncology, the paper does not use traditional "big data" sets but relies on standardized biological models:

  • Cell Lines: RAW 264.7 (mouse macrophages), 4T1 (mouse breast cancer cells), and 3T3 (mouse embryonic fibroblasts).
  • Animal Models: Female C57BL/6 and Balb/c mice were used for in vivo toxicity and anti-tumor efficacy studies.
  • Benchmarks: The performance was compared against saline (control), free Metformin, and various intermediate versions of the nanoparticle (e.g., without the membrane or without the targeting peptide).

Key Insights and Ideas

  • Metformin as an Immunomodulator: The study confirms that Metformin triggers the AMPK signaling pathway, which inhibits the M2 phenotype and promotes M1 markers. This repurposes an affordable, well-understood drug for high-tech cancer therapy.
  • Environmentally Responsive Imaging: Most MRI contrast agents are "always on." By using $MnO_2$, the researchers created a "turn-on" probe. The $Mn^{2+}$ ions (which provide the MRI signal) are only released when the particle reaches the specific chemical conditions of the tumor, reducing background noise and improving diagnostic accuracy.
  • Biomimetic "Stealth": Using macrophage membranes to coat the particles provides "self-recognition" signals (like CD47), allowing the particles to circulate longer in the blood without being eaten by the liver or spleen before reaching the tumor.

Key Results

  • High Loading & Stability: The hollow HMMDN structure achieved a Metformin loading capacity of ~39%. The particles remained stable in PBS for up to 28 days.
  • Superior Imaging: In tumor-like conditions (pH 5.5 + GSH), the longitudinal relaxivity ($r_1$)—a measure of MRI contrast—increased from 0.116 to 8.607 $mM^{-1}s^{-1}$, significantly higher than clinical standards like Gd-DTPA.
  • Effective Repolarization: In vitro, M2 markers (CD206, Arg-1) dropped significantly, while M1 markers (CD80, TNF-$\alpha$, iNOS) surged after treatment.
  • Tumor Inhibition: In 4T1 tumor-bearing mice, the full HMMDN-Met@PM system achieved a tumor inhibition rate of 84.7%, far outperforming free Metformin (~29%).
  • Safety: No significant hemolysis or damage to major organs (heart, liver, spleen, etc.) was observed, indicating high biocompatibility.

Limitations and Future Work

While the results are impressive, the authors and the broader field recognize several hurdles:

  • Complexity of TAMs: The M1/M2 binary is a simplification; in human tumors, macrophages exist on a complex spectrum. Future work needs to address this heterogeneity.
  • Clinical Translation: Scaling up the production of nanoparticles coated with cell membranes is technically challenging and expensive compared to purely synthetic particles.
  • Long-term Immunity: The study focused on the 16-day treatment window. Further research is needed to see if this repolarization leads to long-term "immune memory" that prevents cancer recurrence.

Summary updated

Abstract

Anti-tumor M1-like and pro-tumor M2-like tumor-associated macrophages (TAMs) coexist in tumor microenvironments (TME). The adverse effects of these M1/M2 subsets on tumors directly affect the current strategies to improve anti-tumor immune response. Therefore, it has attracted great attention to change the tumor immunosuppressive microenvironment by reprogramming TAMs. In this paper, we constructed biomimetic nanoparticles (HMMDN-Met@PM) targeting M2-like TAMs for macrophage re-polarization. In detail, the core of the biomimetic nanoparticles is metformin-loaded hollow mesoporous manganese dioxide nanoparticles (HMMDN-Met). Benefited from the hollow and porous structure of HMMDN, metformin, the regulator of M1/M2 adopted in this work, can be easily and widely loaded into HMMDN. Moreover, macrophage membranes were utilized for HMMDN-Met coating (HMMDN-Met@MM) to prevent the premature drug leakage and provide specific molecular recognition/TME targeting. In addition, M2 macrophage targeting peptide (M2pep) was modified on the surface of macrophage membrane to specifically deliver the drug to M2-like TAMs to promote the polarization of M2 to M1 macrophages. Through in vitro and in vivo studies, we found that the expression of surface markers and inflammatory factors CD206, Arg-1 and IL-10 of type M2 macrophages decreased, while the surface markers of type M1 macrophages and the expression of inflammatory factors CD80, TNF-α and iNOS increased, indicating the successful re-polarization of M2 macrophages and finally realizing the inhibition of tumor growth. At the same time, under the acidic and GSH conditions of tumor, HMMDN was decomposed into Mn<sup>2+</sup>, which is a contrast agent for magnetic resonance imaging, thus realizing the tracking of tumor. This work practices biomimetic nanosystem in targeted imaging and immunotherapy, paving the way for strategy designing for tumor inhibition.
BibTeX
@article{chong2023targeting,
  author = {Lijuan Chong and Yao‐Wen Jiang and Dongxu Wang and Pengzhao Chang and Kai Xu and Jingjing Li},
  title = {{Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles}},
  journal = {Journal of Nanobiotechnology},
  year = {2023},
  doi = {10.1186/s12951-023-02122-8},
}
Figure